Frantz Biomarkers

Frantz Biomarkers was a biotechnology company dedicated to the development of non-invasive diagnostic tests for the early detection of cancer, specifically lung cancer. The company's core technology involved a blood-based assay that measured a panel of proteomic biomarkers to identify early-stage malignancies in high-risk populations. By providing a more accessible screening method, the company aimed to improve patient outcomes through earlier intervention and reduced reliance on imaging. The company operated as part of the Frantz Medical Group ecosystem in Ohio and successfully licensed its biomarker panel to other diagnostic firms. Although the company is no longer active, its development efforts focused on clinical validation of its proprietary biomarker signatures.